KR20090033874A - 스타우로스포린을 포함하는 조합물 - Google Patents

스타우로스포린을 포함하는 조합물 Download PDF

Info

Publication number
KR20090033874A
KR20090033874A KR1020097001396A KR20097001396A KR20090033874A KR 20090033874 A KR20090033874 A KR 20090033874A KR 1020097001396 A KR1020097001396 A KR 1020097001396A KR 20097001396 A KR20097001396 A KR 20097001396A KR 20090033874 A KR20090033874 A KR 20090033874A
Authority
KR
South Korea
Prior art keywords
mcl
substituted
typically
lower alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097001396A
Other languages
English (en)
Korean (ko)
Inventor
피터 발렌트
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20090033874A publication Critical patent/KR20090033874A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020097001396A 2006-06-23 2007-06-22 스타우로스포린을 포함하는 조합물 Withdrawn KR20090033874A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612542.1A GB0612542D0 (en) 2006-06-23 2006-06-23 Combinations comprising staurosporines
GB0612542.1 2006-06-23

Publications (1)

Publication Number Publication Date
KR20090033874A true KR20090033874A (ko) 2009-04-06

Family

ID=36803826

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001396A Withdrawn KR20090033874A (ko) 2006-06-23 2007-06-22 스타우로스포린을 포함하는 조합물

Country Status (12)

Country Link
US (1) US20100184820A1 (cg-RX-API-DMAC7.html)
EP (1) EP2037933A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009541240A (cg-RX-API-DMAC7.html)
KR (1) KR20090033874A (cg-RX-API-DMAC7.html)
CN (1) CN101505760A (cg-RX-API-DMAC7.html)
AU (1) AU2007263278A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2655724A1 (cg-RX-API-DMAC7.html)
GB (1) GB0612542D0 (cg-RX-API-DMAC7.html)
MX (1) MX2008016488A (cg-RX-API-DMAC7.html)
RU (1) RU2009101972A (cg-RX-API-DMAC7.html)
WO (1) WO2007147613A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143578A1 (en) * 2008-05-28 2009-12-03 The Council Of The Queensland Institute Of Medical Research Cancer drug target and methods of diagnosis and therapy
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
FI20115640A0 (fi) * 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
CA2878873C (en) 2012-07-13 2018-08-21 Turun Yliopisto A pharmaceutical combination including a histone deacetylase 4 (hdac4) silencing agent for treating cancer
CN110526903B (zh) * 2016-06-01 2021-12-10 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106083830B (zh) * 2016-06-01 2019-07-12 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
SG10201607303YA (en) * 2016-09-01 2018-04-27 Agency Science Tech & Res Antisense oligonucleotides to induce exon skipping
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN107569491A (zh) * 2017-08-30 2018-01-12 杭州科兴生物化工有限公司 一种星孢菌素类化合物的应用
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
CN114437109B (zh) * 2022-03-08 2023-09-29 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种十字孢碱卤代衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
EP1653973A1 (en) * 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines

Also Published As

Publication number Publication date
WO2007147613A3 (en) 2008-07-03
RU2009101972A (ru) 2010-07-27
US20100184820A1 (en) 2010-07-22
CN101505760A (zh) 2009-08-12
CA2655724A1 (en) 2007-12-27
BRPI0713730A2 (pt) 2012-10-30
WO2007147613A2 (en) 2007-12-27
GB0612542D0 (en) 2006-08-02
AU2007263278A1 (en) 2007-12-27
EP2037933A2 (en) 2009-03-25
MX2008016488A (es) 2009-01-22
JP2009541240A (ja) 2009-11-26

Similar Documents

Publication Publication Date Title
US20100184820A1 (en) Combinations comprising staurosporines
ES2269793T3 (es) Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
US11179412B2 (en) Methods of treating conditions involving elevated inflammatory response
US20210161991A1 (en) Uses of hypoxia-inducible factor inhibitors
EP3432886B1 (en) Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers
JP2012144572A (ja) スタウロスポリン誘導体の新規医薬的使用
US20130195926A1 (en) Modulation of nitric oxide signaling to normalize tumor vasculature
EP1778224A2 (en) Flt3 inhibitors for immune suppression
AU2018309739A1 (en) Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
US20240408091A1 (en) Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
AU2011234644B2 (en) PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
US20110190324A1 (en) Methods of treating atherosclerosis
WO2007143630A2 (en) Treatment of neurofibromatosis with hsp90 inhibitors
US20250082652A1 (en) Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases
WO2010009194A1 (en) Methods of treating atherosclerosis
Howard Characterization of the CXCR4-LASP1-eIF4F Axis in Triple-Negative Breast Cancer
WO2021007512A1 (en) Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (gr) binding agents, and/or hsp90 binding agents for uses in treating cancer
HK1095519B (en) The use of staurosporine derivatives for the manufacture of a medicament

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid